One of the pioneers of the prescription digital therapeutics (DTx) sector, Akili Interactive, has decided to abandon that approach and focus exclusively on a direct-to-con
Digital health company Akili has launched a non-prescription version of its attention-deficit hyperactivity disorder (ADHD) digital therapeutic EndeavorRx, that can be dow
Akili Interactive has revealed the findings of a trial of its digital therapeutic (DTx) for attention-deficit hyperactivity disorder (ADHD) in adults, suggesting it may be
Akili has started trading publicly today, raising $163 million as a result of its merger with a blank cheque company, saying the cash injection will help fund further development of its vid
A Japanese language version of Akili Interactive's EndeavorRx ground-breaking digital therapy for attention deficit hyperactivity disorder (ADHD) has started a phase 3 trial, with results d
Digital health company Akili Interactive has agreed a deal that could see its gamified therapy for attention-deficit hyperactivity disorder (ADHD) hosted on the creative gaming platform Rob
Problems at a contract manufacturing organisation have scuppered Eli Lilly’s hopes of a timely FDA approval for lebrikizumab, its IL-13 inhibitor for the treatment of atop
Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho